Transthyretin(TTR) is a protein produced by liver. TTR transport thyroxine and vitamin A to the different parts of body. It is produced from the liver in tetramer form. After the formation it breaks apart into four subunits. These subunits misfold to form amyloid fibrils and the deposition of amyloid fibrils caused a disease called amyloidosis. In most of the cases, these amyloid fibrils start to deposit in heart muscles and thicken the myocardium or wall of the heart. Due to this stiffness heart muscles can not work properly. This condition is called cardiomyopathy. One of the method by which we can prevent the aggregation of misfolded transthyretin protein is to stabilize it. A small organic molecule (Covalent Stabilizer) can bind to it and keep it together. So that it does not break apart and cause amyloidosis. Functional groups which can efficiently stabilize transthyretin are aromatic sulfonyl fluoride and sulfonamide group. In this context, novel sulfonamides tailored with pyrrole 2 carboxylate moiety are synthesized which would be tested against transthyretin cardiac amyloidosis. Due to the broad applicability of sulfonamides, their antiviral, antifungal and anti-inflammatory activity would also be tested. All synthesized compounds have been characterized through FTIR, GCMS and NMR.